re: Ann: MESOBLAST PROVIDES UPDATE ON CLINICA... Ladenburg Thalmann's view on the Prochymal update.
Kevin DeGeeter, Ladenburg Thalmann (4/29/14) "Mesoblast Ltd. expects to meet with the U.S. Food and Drug Administration (FDA) 'shortly' to discuss plans to submit a biologic license application based on existing clinical data, including data from an expanded access program. . .in our view, an update on the program is likely in June 2014 following distribution of written minutes from the FDA meeting. . .we reiterate our Buy rating with a $52 price target."
http://www.thelifesciencesreport.com/pub/co/4251
Note:the current (MBLTY) -Other OTC SP is US$22.30
+13 job applications and 2 recent major league appointments (in Pharma industry).
Please DYOR and Good luck to all.
- Forums
- ASX - By Stock
- MSB
- Ann: MESOBLAST PROVIDES UPDATE ON CLINICAL PROGRA
Ann: MESOBLAST PROVIDES UPDATE ON CLINICAL PROGRA, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
-0.060(5.63%) |
Mkt cap ! $1.153B |
Open | High | Low | Value | Volume |
$1.04 | $1.04 | $1.00 | $2.096M | 2.059M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 19145 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 32611 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 138918 | 1.000 |
9 | 51525 | 0.995 |
11 | 57206 | 0.990 |
8 | 419501 | 0.985 |
8 | 30871 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
1.010 | 32460 | 13 |
1.015 | 50524 | 10 |
1.020 | 97181 | 10 |
1.025 | 48217 | 5 |
1.030 | 81170 | 5 |
Last trade - 12.31pm 04/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |